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http://www.biolres.com/content/47/1/70RESEARCH ARTICLE Open AccessSimultaneous silencing of VEGF and KSP by siRNA
cocktail inhibits proliferation and induces
apoptosis of hepatocellular carcinoma Hep3B cells
Chung Chinh Doan1,2*, Long Thanh Le2, Son Nghia Hoang2, Si Minh Do1 and Dong Van Le3Abstract
Background: Vascular endothelial growth factor (VEGF) is involved in the growth of new blood vessels that feed
tumors and kinesin spindle protein (KSP) plays a critical role in mitosis involving in cell proliferation. Simultaneous
silencing of VEGF and KSP, an attractive and viable approach in cancer, leads on restricting cancer progression. The
purpose of this study is to examine the therapeutic potential of dual gene targeted siRNA cocktail on human
hepatocellular carcinoma Hep3B cells.
Results: The predesigned siRNAs could inhibit VEGF and KSP at mRNA level. siRNA cocktail showed a further
downregulation on KSP mRNA and protein levels compared to KSP-siRNA or VEGF-siRNA, but not on VEGF expression.
It also exhibited greater suppression on cell proliferation as well as cell migration or invasion capabilities and induction
of apoptosis in Hep3B cells than single siRNA simultaneously. This could be explained by the significant downregulation
of Cyclin D1, Bcl-2 and Survivin. However, no sigificant difference in the mRNA and protein levels of ANG2, involving
inhibition of angiogenesis was found in HUVECs cultured with supernatant of Hep3B cells treated with siRNA
cocktail, compared to that of VEGF-siRNA.
Conclusion: Silencing of VEGF and KSP plays a key role in inhibiting cell proliferation, migration, invasion and
inducing apoptosis of Hep3B cells. Simultaneous silencing of VEGF and KSP using siRNA cocktail yields promising
results for eradicating hepatocellular carcinoma cells, a new direction for liver cancer treatment.
Keywords: Vascular endothelial cell growth factor (VEGF), Kinesin spindle protein (KSP), siRNA cocktail, Proliferation,
Apoptosis, Hepatocellular carcinomaBackground
Primary liver cancer, hepatoblastoma (HB) and hepatocel-
lular carcinoma (HCC), is one of the most common solid
tumors, ranking the fifth in most common malignancy
worldwide and the second cause of cancer-related deaths.
The major therapeutic strategies in solid tumors as well as
HCC are excision of the primary tumor, followed by radio-
therapy and chemotherapy. However, in some cases, this
treatment still leaves some problems such as metastatic re-
activation and subsequent tumor recurrence [1]. Recently,* Correspondence: dcchung@hcmus.edu.vn
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unless otherwise stated.following the rapid advances in molecular biology, many
new therapeutic strategies, including RNA interference
(RNAi) technology for treating liver cancer at genetic level
have been developed [2]. RNAi is a specific gene regula-
tory mechanism in which activation of an intracellular
pathway triggered by small-interfering RNA (siRNA) of
21–23 nucleotides (nt), leading to gene silencing through
degradation of a homologous target mRNA [3]. The se-
lective and robust effect of RNAi on gene expression
makes it become a valuable tool for basic research in
biology, and thereby continue to have a major impact
on medical science [4]. Another unique advantage of
RNAi is that non-druggable protein targets can also be
efficiently knocked-down and possibly achieve thera-
peutic effects [5]. Therefore, RNAi-based therapeutic
strategy presents an effective and simple approach in
new area of clinical therapy for HCC.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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KSP-siRNA #1 Sense: CUGAAGACCUGAAGACAAUdTdT
Antisense: AUUGUCUUCAGGUCUUCAGdTdT
KSP-siRNA #2 Sense: UCGAGAAUCUAAACUAACUdTdT
Antisense: AGUUAGUUUAGAUUCUCGAdTdT
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disease involving abnormal cell growth. As a new member
of the kinesin superfamily of microtubule-based motors,
kinesin Eg5, also called kinesin spindle protein (KSP) or
KIF11 participates in mitosis, by separating the microtu-
bules that are attached to the two centrosomes, and
contributing to the bipolar arrangement of the spindles
[6]. Thus, inhibition of KSP may block the formation of
bipolar mitotic spindles of mitotic cells, causing cell-cycle
arrest, activation of the mitotic checkpoint, induction of
apoptosis and eventually, to cell death [5,7]. KSP gene was
found to be lowly expressed in normal primary cells, but
higher in transformed cells . Its expression was also higher
in breast, colon, lung, ovary, and uterine carcinomas than
in their adjacent tissues [8]. The overexpression of KSP as
a transgene may cause genomic instability and tumor
formation in mice [9]. In addition, KSP gene was also
frequently expressed in HCC tissues and there was also
a strong correlation between the level of KSP expression
and HCC development [10]. These findings have indicated
that the important role of KSP in mitotic progression
makes it an significant candidate of anticancer therapy.
Several KSP inhibitors have been studied in clinical trials
and showed efficacy in preclinical models of human tu-
mors [10,11]. However, more trials must be studied to test
their efficacy in clinic due to the toxicological side effects
of KSP inhibitors, such as the observed neutropenia and
leukopenia [12].
Additionally, the ability of the highly vascularized tu-
mors, including HCC to attract blood vessels (tumor
angiogenesis) is one of the rate-limiting steps for tumor
progression [13]. Angiogenesis is governed differently
by multiple factors, including growth factors, cytokines,
chemokines, enzymes, and adhesion molecules, but the
most important one is vascular endothelial growth factor
(VEGF) [14]. Among all family members of VEGF, VEGF-A
is the most potent and specific angiogenic factor. Many
studies have shown that VEGF, mainly VEGF-A, is fre-
quently expressed in HCC and increased VEGF levels
correspond to increased tumor sizes [14,15]. Another
study reported that there was also a strong correlation
between the level of VEGF expression and HCC patho-
logical grading and clinical stages [16]. In addition, VEGF
was identified as a key hypoxia-induced angiogenic stimu-
lator in liver cancer [14]. It was suggested that the gene
plays a critical role in the HCC progression of tumor
growth. Therefore, VEGF is a logical target for HCC ther-
apy. For the last decade, there have been several options of
inhibiting VEGF binding to its receptors which have been
developed as anticancer agents, such as soluble VEGF
receptors, humanized anti VEGF monoclonal antibody
(Bevacizumab; Avastin), various small molecules inhibiting
VEGFR2 signal transduction [17,18]. However, the use of
anti VEGF antibodies or other inhibitors is responsible forunexpected toxic side effects, especially in terms of
thromboembolic events and bleeding that require further
investigation [18]. It is therefore a challenge to explore a
new approach to inhibit VEGF expression in identification
of novel druggable targets.
In this study, we aimed to use siRNA cocktail which tar-
gets VEGF-A (referred here as VEGF) and KSP gene as a
therapy for HCC treatment. Pre-designed VEGF and KSP
siRNAs were screened in Hep3B cell line, isolated from
liver biopsy specimens with primary HCC and widely used
as an experimental model. The best siRNA targets were
used as cocktail to inhibit the growth, migration, invasion
and induce apoptosis of Hep3B cells. The effect of siRNA
cocktail on inhibiting in vitro angiogenesis ability of
HUVECs induced by Hep3B cells was also evaluated.
Results
Effects of pre-designed siRNAs on KSP and VEGF mRNA
expression in Hep3B cells
To address the functions of VEGF and KSP, Hep3B cells
were transfected with VEGF-siRNAs and KSP-siRNAs.
Subsequently, the relative mRNA levels were determined
by Real-time qRT-PCR after treatments for 72 hours. For
validation purposes, three different siRNAs targeting
different regions of human VEGF or KSP were employed
(Table 1). Then, one with best repressive effect was used
in following experiments.
As shown in Figure 1A, Real-time qRT-PCR revealed that
the inhibition of VEGF expression in the VEGF-siRNA#1,
VEGF-siRNA#2, and VEGF-siRNA#3 groups were 77.88 ±
2.02%, 52.68 ± 1.86% and 38.52 ± 2.56% respectively,
compared to the untreated group (p < 0.05 and p < 0.01,
Figure 1A). In the same manner, the silencing effects of
KSP-siRNAs also observed in the KSP-siRNA#1, KSP-
Figure 1 Effects of pre-designed siRNAs treatments on VEGF and KSP mRNA expression in Hep3B cells. Cells were transfected with siRNAs.
Total RNA was extracted from cells at 72 hours after siRNA transfection. The mRNA relative level of VEGF (A) and KSP (B) with siRNAs treatments in
Hep3B cells by Real-time qRT-PCR. The mRNA expressions of VEGF and KSP were normalized with β-actin. Values were given as mean value ± standard
deviation (SD) of triplicate. **p < 0.01 and *p < 0.05 compared to untreated cell group.
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76.72 ± 2.27% and 58.86 ± 1.52%, respectively, compared
to the untreated group (p < 0.05 and p < 0.01, Figure 1B).
No significant difference was identified between CONT-
siRNA treated cells and control untreated ones. VEGF-
siRNA#1 and KSP-siRNA#2, directed at VEGF and KSP,
respectively, were selected as the most effective inhibitors
for investigation in further experiments.Effects of VEGF-siRNA#1, KSP-siRNA#2 and siRNA cocktail
on KSP and VEGF expression in Hep3B cells
VEGF-siRNA#1, KSP-siRNA#2, siRNA cocktail (mixed by
VEGF-siRNA#1 and KSP-siRNA#2 equally) and CONT-
siRNA were transfected into Hep3B cells. The levels of
mRNA of VEGF and KSP were determined using Real-
time qRT-PCR techniques and protein expression was de-
tected by Western blot and ELISA after treatment with
siRNAs for 72 hours. As demonstrated in Figure 2A,
VEGF-siRNA#1 inhibited VEGF expression at the mRNA
level up to 75.32 ± 3.03%, after 72 hours while it was not
much altered in CONT-siRNA transfected cells compared
to that of the untreated ones (p < 0.01, Figure 2A). A silen-
cing effect of VEGF-siRNA#1 was observed at the protein
level up to 57.86 ± 3.35% by Western blot analysis and
densitometric analysis (p < 0.05, Figure 3A and B). Down-
regulation of VEGF protein was also confirmed by ELISA
analysis (Figure 3D). Interestingly, we found that VEGF
was silenced by VEGF-siRNA, but KSP was also inhib-
ited by it at mRNA level up to 40,67 ± 2.96% (p < 0.05,
Figure 2B), and the detection of protein expression was
confirmed by downregulation, protein level up to 31.74 ±
2.38% (p < 0.05, Figure 3C) compared to untreated cells.Similarly, KSP expression was effectively inhibited by
KSP-siRNA#2 at both mRNA and protein levels by 75.07 ±
3.56% (p < 0.01, Figure 2B) and 53.48 ± 2.19% (p < 0.05,
Figure 3C) by Real-time qRT-PCR analysis and Western
blot analysis, respectively. These values indicated that
the effective silencing of KSP-siRNA#2 on both mRNA
and protein levels of KSP. As shown in Figures 2 and 3,
KSP-siRNA#2 did not produce any effect on the VEGF
expression at the mRNA and protein levels.
Eventually, we examined siRNA cocktail on VEGF and
KSP expressions respectively. As shown in Figures 2 and
3, siRNA cocktail inhibited the VEGF and KSP expression
at the mRNA and protein levels, obviously in comparison
to the untreated ones. The results showed that VEGF
mRNA was downregulated by 77.54 ± 3.22% (p < 0.01,
Figure 2A) and VEGF protein level was downregulated
by 59.42 ± 2.14% (p < 0.05, Figure 3B), which was also
confirmed by ELISA analysis compared to untreated
cells (Figure 3D). Downregulation of VEGF by siRNA
cocktail was similar with that of VEGF-siRNA#1. When
compared to VEGF-siRNA#1 or KSP-siRNA#2 alone, the
siRNA cocktail showed higher inhibition on KSP mRNA
expression up to 85.77 ± 1.78% (p < 0.01, Figure 2B) and
protein level up to 69.42 ± 2.11% (p < 0.05, Figure 3C),
indicating a significant effect of siRNA cocktail on KSP
expression.
Effects of VEGF-siRNA#1, KSP-siRNA#2 and siRNA cocktail
on cell proliferation in Hep3B cells
The silencing effects of VEGF and KSP on cell prolifera-
tion of Hep3B cells were detected by WST-1 assay and
clonogenic survival assay. The absorbance values of the
Hep3B cells at 48 and 72 hour post-transfection with
Figure 2 Effects of different treatments on VEGF and KSP mRNA expression in Hep3B cells. The mRNA relative level of VEGF (A) and KSP
(B) with different treatments in Hep3B cells by Real-time qRT-PCR. The mRNA expressions of VEGF and KSP were normalized with β-actin. Values
were given as mean value ± standard deviation (SD) of triplicate. **p < 0.01, *p < 0.05 compared to untreated cell group and #p < 0.05 compared
to siRNA cocktail treated cell group.
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were significantly lower than those of the untreated cells
(both p < 0.01, Figure 4A). There was no significant dif-
ference between the growth of cells treated with VEGF-
siRNA#1 and that of KSP-siRNA#2. The absorbance value
of Hep3B cells treated with siRNA cocktail showed a sig-
nificant decrease in cell proliferation compared to the cells
treated with either VEGF-siRNA#1 or KSP-siRNA#2 at 48
or 72 hours, respectively (both p < 0.05, Figure 4A). These
results were also further supported by clonogenic sur-
vival assay (Figure 4B). A highly-significant decline of
the cloning efficiency was observed in VEGF-siRNA#1
treated group (p < 0.05) and KSP-siRNA#2 treated group
(p < 0.05) as well as siRNA cocktail treated group (p < 0.01)
in comparison to untreated cells. The inhibition rate
treated with siRNA cocktail showed a significant de-
crease in colony formation compared to the cells treated
with either VEGF-siRNA#1 or KSP-siRNA#2 (both p < 0.05,
Figure 4B and C).Effects of VEGF-siRNA#1, KSP-siRNA#2 and siRNA cocktail
on cell migration ability in Hep3B cells
Wound-healing assay was used to evaluate the migration
ability of Hep3B cells after different treatments. As illus-
trated in Figure 5A, the scratch caused in groups of un-
treated and CONT-siRNA nearly closed completely after
72 hours, but the cells in treatment with siRNA cocktail
and VEGF-siRNA#1 or KSP-siRNA#2 were not able to
move toward the center of the wound. Moreover, siRNA
cocktail exhibited a decrease in wound healing ability
compared to VEGF-siRNA#1 or KSP-siRNA#1 alone
(both p < 0.05, Figure 5B).Effects of VEGF-siRNA#1, KSP-siRNA#2 and siRNA cocktail
on cell invasion ability in Hep3B cells
We also performed transwell assay to evaluate the effects
of VEGF-siRNA#1, KSP-siRNA#2 and siRNA cocktail on
Hep3B cell invasion. Hep3B cells were treated with siR-
NAs and loaded to the transwell chambers (the upper
surface of the transwell filters was coated with matrigel).
After 48 hours, cells migrated to the underside of the
transwell filters were stained with crystal violet solution
and imaged (Figure 6A). As shown in Figure 6, VEGF-
siRNA#1, KSP-siRNA#2 and siRNA cocktail significantly
suppressed the ability of Hep3B cell to invade to the under-
side of the transwell filters. And obviously, treatment with
siRNA cocktail resulted in a significant decrease of inva-
sion ability compared to that of VEGF-siRNA#1or KSP-
siRNA#2 alone treated cells (both p < 0.05, Figure 6B).
Effects of VEGF-siRNA#1, KSP-siRNA#2 and siRNA cocktail
on apoptosis in Hep3B cells
Annexin V-FITC/PI double staining and flow cytometry
analysis were performed to evaluate the ability of siRNA
cocktail, VEGF-siRNA#1, or KSP-siRNA#2 on inducing
Hep3B cell apoptosis. As Figure 7 illustrated, the apop-
tosis rate of Hep3B cells was significantly increased by
VEGF-siRNA#1 treatment (23.25 ± 0.56%) compared to
the untreated cells (p < 0.01). Similarly, an increase was
also identified by KSP-siRNA#2 transfection (20.38 ± 0.89%,
p < 0.01). In addition, the rate of apoptotic cells were greatly
increased by siRNA cocktail treatment (33.62 ± 1.25%,
p < 0.01). There was no significant difference between
the apoptosis rate of the CONT-siRNA treated cells
and that of untreated ones. And obviously, treatment
with siRNA cocktail resulted in a significant increase of
Figure 3 Effects of different treatments on VEGF and KSP protein expression in Hep3B cells. (A) The protein expressions of VEGF and KSP
were examined by Western blot analyses. β-actin was used as a housekeeping gene control. The size of each protein was indicated. (B, C) The siRNAs
transfected cells exhibited a decreased expression of VEGF protein (B) and KSP protein (C) as confirmed by densitometric analysis. (D) The cell culture
supernatants were collected at 72 hours after transfection and the secreted VEGF concentrations were measured by the quantitative VEGF ELISA kit.
Values were given as mean value ± standard deviation (SD) of triplicate. **p < 0.01, *p < 0.05 compared to untreated cell group and #p < 0.05 compared
to siRNA cocktail treated cell group.
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siRNA treated cells (both p < 0.05, Figure 7B).
Inhibition of Cyclin D1, Bcl-2 and Survivin expression in
Hep3B cells by VEGF-siRNA#1, KSP-siRNA#2 and siRNA
cocktail
Downstream targets of Cyclin D1, Bcl-2, and Survivin were
also downregulated at both protein and mRNA levels. The
relative levels of mRNA of Cyclin D1, Bcl-2 and Survivin
were also determined using Real-time RT-qPCR. The
mRNA levels of Cyclin D1 and Bcl-2 were downregu-
lated by 48.21 ± 5.02%, 51.77 ± 3.52% and 64.23 ± 4.02%
(Figure 8A); 47.57 ± 2.04%, 43.72 ± 4.23% and 60.74 ±
5.02% (Figure 8B), whereas the mRNA levels of Survi-
vin were downregulated by 57.64 ± 4.05%, 55.75 ± 5.03%
and 70.12 ± 4.26% (Figure 8C) in VEGF-siRNA#1, KSP-siRNA#2 and siRNA cocktail transfected Hep3B cells in
comparison to the untreated cells, respectively (p < 0.05
and p < 0.01, Figure 8). Similarly, both Cyclin D1, Bcl-2
and Survivin protein expressions were measured by using
Western blot analyses (Figure 9A). The protein levels of
Cyclin D1 and Bcl-2 were downregulated by 32.62 ± 2.38%,
29.12 ± 3.05% and 45.78 ± 2.54% (Figure 9B); 36.34 ± 3.05%,
38.13 ± 2.19% and 47.92 ± 1.15% (Figure 9C), and Survivin
protein expressions were decreased by 42.70 ± 2.56%,
43.05 ± 3.84% and 56.92 ± 2.05% (Figure 9D) in VEGF-
siRNA#1, KSP-siRNA#2 and siRNA cocktail transfected
Hep3B cells compared to the untreated cells, respectively
(p < 0.05 and p < 0.01, Figure 9). siRNA cocktail showed
greater decrease of Cyclin D1, Bcl-2, Survivin expression
at both mRNA and protein levels in comparison to VEGF-
siRNA#1 or KSP-siRNA#2 alone (p < 0.05 and p < 0.01,
Figure 4 Effects of different treatments on the growth and the colony formation in Hep3B cells. (A) The proliferation of Hep3B cells was
measured using WST-1 kit. The growth curve of Hep3B cells was shown for each group. The proliferation was assayed in triplicates at 0, 24, 48 and 72
hour post-transfection of siRNAs. (B) Effects of different treatments on the inhibition of cell proliferation were confirmed by the total numbers of colony.
(C) Representative images of the colony formation assay were shown. Values were given as mean value ± standard deviation (SD) of triplicate. **p < 0.01,
*p < 0.05 compared to untreated cell group; #p < 0.05 compared to siRNA cocktail treated cell group.
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mRNA and protein levels of Cyclin D1, Bcl-2 and Sur-
vivin between CONT-siRNA treated cells and untreated
ones.
Effects of VEGF-siRNA#1, KSP-siRNA#2 and siRNA cocktail
on tube formation in HUVECs
A HUVECs angiogenesis model was employed to evaluate
the tube formation of HUVECs stimulated by the conditioned
medium derived from Hep3B cells transfected with siRNA
cocktail, VEGF-siRNA#1, KSP-siRNA#2 and CONT-siRNA.
As illustrated in Figure 10, siRNA cocktail or VEGF-
siRNA#1 transfected Hep3B cells inhibited HUVECs to
form extensive and enclosed tube networks on Matrigel
as compared to the CONT-siRNA treated cells and un-
treated ones (p < 0.05, Figure 10B). However, KSP-siRNA#2
treated cells did not affect on tube formation in HUVECs.
We also determined the mRNA and protein levels of
ANG2 in HUVECs. In normally cultured negative controlcells, the expression of ANG2 mRNA (11.24 ± 2.15%) and
protein (18.24 ± 1.88%) was slight, when compared to the
untreated cells (Figure 11). CONT-siRNA did not cause
any statistical differences compared to untreated cells. In
VEGF-siRNA#1 treated cells, the expression of ANG2
mRNA (41.66 ± 3.03 %, p < 0.05, Figure 11A) and protein
(59.62 ± 1.84 %, p < 0.05, Figure 11B) was significantly
reduced compared to untreated cells. siRNA cocktail
treated cells (ANG2 mRNA: 39.82 ± 2.78%; protein: 53.86 ±
1.84%) exhibited similar effect with VEGF-siRNA#1 treated
cells. In contrast, the result was not reproduced by KSP-
siRNA#2, which showed no significant difference in ANG2
expression in HUVECs between KSP-siRNA#2 treated cells
and untreated ones (Figure 11).
Discussion
As tumor cells are characterised by multiple genetic and
epigenetic alterations, the single inhibition of one tumour-
associated gene as a therapeutic strategy may not be
Figure 5 Effects of different treatments on cell migration in Hep3B cells. The cells with different treatments at 0, 24, 48, and 72 hours.
(A) Representative images of the cell migration ability assay were shown. (B) Effects of different treatments on migration ability of Hep3B cells
were determined by the cell relative migration distances in different time points. Value were presented as mean value ± standard deviation (SD) of
triplicate. **p < 0.01, *p < 0.05 compared to untreated cell group and #p < 0.05 compared to siRNA cocktail treated cell group.
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been well known that gene therapy targeting either
VEGF or KSP alone may cause inhibition of HCC growth
[14,19]. However, the current finding showed that siRNA
cocktail silencing VEGF and KSP together could inhibit
the proliferation, migration or invasion of HCC cells better
than single siRNA simultaneously. On the other hand, the
siRNA cocktail might also increase apoptosis induction in
HCC cells. This is a better therapeutic strategy which
could be adopted in clinics.
As one of the most important angiogenesis-stimulating
factors, VEGF is correlated with liver cancer progression
through its action of tumor neovascularization, tumor in-
vasion and metastasis [14-16]. Some reports have shown
that siRNA-mediated downregulation of VEGF expressionresults in decreased proliferation and induced apoptosis in
colorectal cancer cells [20], prostate cancer cells [21], gas-
tric cancer cells [22]. Our results also demonstrated that
siRNA targeting VEGF could inhibit proliferation, migra-
tion, invasion and induce apoptosis in hepatocellular
carcinoma Hep3B cells. Our observations were consistent
with a previous report that also used VEGF-siRNA to sup-
press VEGF expression in liver cancer cells [14]. To eluci-
date its molecular mechanisms of VEGF inhibiting cell
proliferation and inducing apoptosis, we have examined
the expressions of the key regulators Cyclin D1, Bcl-2 and
Survivin. Our results demonstrated that the expression
levels of Cyclin D1, Bcl-2 and Survivin were significantly
decreased in Hep3B cells upon cell transfection with
VEGF-siRNA. Cyclin D1 is known to accumulate during
Figure 6 Effects of different treatments on cell invasion in Hep3B cells. The cells were treated with different treatments. After 48 hours, cells
migrated to the underside of the transwell filters were stained with Crystal Violet solution and imaged. (A) Representative images of the cell
invasion ability assay were shown. (B) Effects of different treatments on invasion ability of Hep3B cells were determined by the total numbers of
invading cell. Value were presented as mean value ± standard deviation (SD) of triplicate. **p < 0.01, *p < 0.05 compared to untreated cell group
and #p < 0.05 compared to siRNA cocktail treated cell group.
Figure 7 Effects of different treatments on the induction of apoptosis in Hep3B cells. (A) Cell apoptosis was detected by Annexin V-FITC/PI
double staining and FCM analysis. Cells in the lower left (LL) quadrant represented survivals; lower right (LR) quadrant represented early apoptosis;
the upper right (UR) quadrant represented necrosis or post-apoptotic and the upper left (UL) quadrant represented detection of error allowed.
(B) Values (intensity of fluorescent positive cells during early apoptotic events) were given as mean value ± standard deviation (SD) of triplicate.
**p < 0.01 compared to untreated cell group, #p < 0.05 compared to siRNA cocktail treated cell group.
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Figure 8 Effects of different treatments on Cyclin D1, Bcl-2 and Survivin mRNA expression in Hep3B cells. The mRNA levels of Cyclin D1
(A), Bcl-2 (B) and Survivin (C) in Hep3B cells were determined by Real-time qRT-PCR after 72 hours of siRNA transfection. The mRNA expression of
these genes was normalized with β-actin. Values were given as mean value ± standard deviation (SD) of triplicate. **p < 0.01, *p < 0.05 compared
to untreated cell group and ##p < 0.01, #p < 0.05 compared to siRNA cocktail treated cell group.
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D1 may be a frequent event in hepatocarcinogenesis and
therefore plays an important role in growth of liver tumors
[23]. In contrast, Bcl-2 and Survivin are thought to be very
important anti-apoptotic proteins in cells. They are identi-
fied to be one of the mechanisms involved by cancer cells
to evade apoptosis. Bcl-2, a prominent member of the
Bcl-2 family proteins, is responsible for governing the
release of cytochrome c from the mitochondrial mem-
brane, the activation of caspase cascade, the execution
of apoptosis, and finally, to the prevention of death in
cancer cells [24]. Overexpression of Bcl-2 also may protect
human hepatoma cells from antibody mediated apoptosis
[25]. Similarly, Survivin, belong to the inhibitors of apop-
totic proteins (IAPs), has been implicated in both cell div-
ision and inhibition of apoptosis. By inhibiting apoptosis
and promoting mitosis, Survivin may confer cancer cell
survival and growth. Unlike other members of IAP family,Survivin is lowly or not expressed in normal tissues, but
highly in tumor tissues. The induction of apoptosis is
generally associated with suppression of Survivin within
tumor cells [26]. The overexpression of Survivin in the
majority of human tumor types, including liver cancer,
can prevent apoptosis by binding and inhibiting pro-
apoptotic caspases as a microtubule stabilizer during
mitosis, and promote cell cycle progression [27].
In contrast to microtubules which are also presented
in post-mitotic cells, KSP is exclusively expressed in mi-
totic cells, which makes it an important target for anti-
mitotics [6]. Therefore, inducing a degradation of KSP
by siRNA was expected to lead to a novel approach for
the control of cancer cells. In this study, the expression
of KSP was downregulated at both mRNA and protein
levels in Hep3B cells by KSP-siRNA transfection. This re-
sult was similar with reports using KSP-siRNA to monitor
the expression of KSP in ovary cancer cells [5], cervical
Figure 9 Effects of different treatments on Cyclin D1, Bcl-2 and Survivin protein expression in Hep3B cells. (A) The protein expressions of
Cyclin D1, Bcl-2 and Survivin in Hep3B cells were measured by Western blot analyses after 72 hours of siRNA transfection. β-actin was used as a
housekeeping gene control. The size of each protein was indicated. (B, C, D) Densitometric analyses of these three proteins Cyclin D1 (B), Bcl-2
(C) and Survivin (D) were made relative to β-actin. Values were given as mean value ± standard deviation (SD) of triplicate. *p < 0.05 compared to
untreated cell group and #p < 0.05 compared to siRNA cocktail treated cell group.
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and breast carcinoma cells [8]. In addition, our study
also indicated that KSP-siRNA could inhibit proliferation,
migration/invasion and induce apoptosis of Hep3B cells.
The expression of genes involved in anti-apoptosis (Bcl-2
and Survivin) and proliferation (Cyclin D1) was downreg-
ulated in KSP-siRNA transfected cells. From these results,
we surmised that the downregulation of Cyclin D1, Bcl-2
and Survivin expressions by VEGF-siRNA or KSP-siRNA
transfection in one of the important ways to induce cell
apoptosis, subsequently leading cell death.
It has been reported that siRNA cocktail was composed
of two different siRNA sequences showed more effective
inhibition of the two corresponding target genes at one
time than siRNA alone [28]. In present study, we prepared
the siRNA cocktail of best siRNAs, analyzed the celltreated with siRNA cocktail and controls, including sin-
gle siRNA targeting VEGF or KSP and negative control
siRNA. Our results revealed that using the siRNA cock-
tail targeting VEGF and KSP to inhibit the proliferation,
migration, invasion and induce apoptosis of Hep3B cells
was better than each siRNA alone. This could be explained
by the significant downregulation of Cyclin D1, Bcl-2 and
Survivin following the treatment of siRNA cocktail as
compared to single siRNA simultaneously. Our results
corresponded with several previous studies reporting the
influences of siRNA cocktail on cell growth and apoptosis
of gastric cancer cells [28], pancreatic cancer cells [29] and
colorectal cancer cells [30]. The siRNA cocktail exhibited
specific and high efficiency on silencing multi genes simul-
taneously and would have great potential for therapeutic
siRNA applications.
Figure 10 The tube formation inhibition of different treatments was detected in HUVECs angiogenesis model. (A) Representative photographs
of each treatments were shown. (B) The total numbers of branching points were decreased by treatment of siRNA cocktail, VEGF-siRNA#1 and
KSP-siRNA#2 compared to the untreated. Values were given as mean value ± standard deviation (SD) of triplicate. *p < 0.05 compared to untreated cell
group.
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http://www.biolres.com/content/47/1/70Interestingly, we found that VEGF-siRNA exhibited sig-
nificant inhibition on KSP mRNA and protein levels, while
the KSP-siRNA alone did not show any effect on VEGF
expression. We assumed that VEGF might be acted as a
KSP upstream regulator, which could probably lead to
downregulation of KSP expression. The fact that VEGF-
siRNA presented similar KSP-siRNA effects on prolifera-
tion, migration, invasion and apoptosis of Hep3B cells
suggesting that one of inhibiting tumor growth mecha-
nisms of VEGF-siRNA functioned through inhibition of
KSP expression. Furthermore, we also found that the
expression of KSP protein was suppressed to a greater
extent in the siRNA cocktail treated group than that in
the KSP-siRNA or VEGF-siRNA alone group, indicating
a significant silencing effect of siRNA cocktail on KSP pro-
tein expression. The results were supported by the highest
inhibition of proliferation, migration, invasion and induc-
tion of apoptosis on Hep3B cells by the siRNA cocktail as
compared to each of siRNAs alone. In contrast, suppres-
sion on VEGF expression in Hep3B cells by the siRNA
cocktail was similar to that by the VEGF-siRNA, which
supported the observation that KSP-siRNA did not in-
fluence VEGF protein expression. This observation was
also demonstrated by angiogenesis and ANG2 expres-
sion on the HUVECs induced by Hep3B cell culture media
following siRNAs treatment. A previous study indicatedthat HUVECs was induced to form new blood vessels with
higher VEGF concentration [31]. In addition, ANG2 which
is expressed in the areas undergoing vascular remodeling
and leads to decreased vessel maturation and enhanced
vessel sprouting could be upregulated by VEGF in endothe-
lial cells [32]. ANG2 inhibition prevents the growth of new
vessels by endothelial sprout formation [33]. In our study,
the results showed that inhibition of capillary tube-like
structure formation and suppression of ANG2 expres-
sion in HUVECs by siRNA cocktail was relatively equal
when compared to VEGF-siRNA. Meanwhile, KSP-siRNA
showed no effect on inhibiting tube formation as well as
ANG2 expression in HUVECs. These results demonstrated
that VEGF acts as a KSP upstream regulator promoting the
effect of KSP on Hep3B cells. More importantly, our esti-
mates were strongly supported by another study reporting
a strong upregulation of KSP or Eg5 expression after appli-
cation of recombinant human VEGF on the differentiated
day-13 chick chorio-allantoic membrane (CAM). The re-
sults showed that numerous known genes encoding mitotic
kinesins were consistently upregulated by VEGF, including
KIF4A, KIF11/Eg5, KIF15, KIF20A/Mklp2 and KIF23 [34].
Conclusion
This study showed that the expression of KSP was inhib-
ited by VEGF-siRNA, suggesting that VEGF serves as an
Figure 11 Effects of different treatments on ANG2 expression in HUVECs cultured with Hep3B supernatant. HUVEC complete medium
(without VEGF) was used as a negative control. (A) ANG2 mRNA expression levels were showed by Real-time qRT-PCR analysis. (B) ANG2 protein
in HUVECs was determined by Western Blot analysis. (C) Densitometric analysis of ANG2 protein was made relative to β-actin. Values were given
as mean value ± standard deviation (SD) of triplicate. *p < 0.05 compared to untreated cell group.
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http://www.biolres.com/content/47/1/70upstream regulator of KSP gene expression. Although
there were several reports using siRNA to inhibit VEGF
or KSP, combined siRNA therapy to simultaneously re-
duce VEGF and KSP expression was proved to be an
effective approach to inhibit cell growth and induce
apoptosis of HCC cells. This could be a new targeted
strategy to eradicate HCC cells.
Methods
This experimental study was approved by the Committee
for Ethics in Research, University of Science, Vietnam
National University.
Culture of cells
Hep3B cell line (hepatocellular carcinoma cells, HB-8064),
HUVECs cell line (human umbilical vein endothelial cells,CRL-1730) were purchased from the American Type
Culture Collection (ATCC, Rockville, MD, USA). Hep3B
cells were thawed and cultured in DMEM-F12, supple-
mented with 10% FBS and 0.5% antibiotic-mycotic (All
were bought from Sigma-Aldrich, St. Louis, MO, USA).
HUVECs cells were thawed and cultured in endothelial
cell growth medium-2 (EGM-2) (Lonza, Walkersville, MD,
USA), supplemented with 10% FBS and 0.5% antibiotic-
mycotic. All cells were maintained at 37°C, 5% CO2.
Transfection of siRNAs
The sequences of the siRNAs targeting VEGF-A (VEGF-
A-siRNA, also simply referred to as VEGF-siRNA), siR-
NAs targeting KSP (KSP-siRNA) and mismatched siRNA
(CONT-siRNA) were shown in Table 1. All siRNAs were
synthesized by Bioneer (Daejeon, Republic of Korea). Each
Doan et al. Biological Research 2014, 47:70 Page 13 of 15
http://www.biolres.com/content/47/1/70siRNA was resuspended in nuclease – free water and
the stock solutions were stored at 4°C until use. The
cells were divided into five groups with different treat-
ments at final concentration of 20 nM: Group 1: un-
treated cell group, group 2: CONT-siRNA treated cell
group, group 3: VEGF-siRNA treated cell group, group 4:
KSP-siRNA treated cell group, group 5: siRNA cocktail
treated cell group (VEGF-siRNA mixed with KSP-siRNA
at equal concentration). All the above siRNAs were transi-
ently transfected with a Lipofectamine RNAiMAX Trans-
fection Reagent kit (Invitrogen Inc., Carlsbad, CA, USA)
by reverse transfection protocol. Briefly, for each well of
24-well plate (Corning Costar Corp., Cambridge, MA), 3μl
of siRNA duplex (20μM) was mixed with 1 μl transfection
reagent and 100 μl Opti-MEM medium supplied with the
kit. Then, the siRNA-transfection reagent complex was in-
cubated with 500 μl of diluted cells (5 × 104 cells/ well) for
24-72 hours at 37°C, 5% CO2. Control cells (untreated
with siRNAs) were also grown under the same condition.
The siRNAs treated cells and control cells were harvested
during time intervals for transfection efficiency analysis.
Real-time quantitative reverse transcription PCR (real-time
qRT-PCR)
Total RNA was extracted using RNeasy Mini Kit (Qiagen,
Valencia, CA, USA). The concentration of RNA was
measured using a Biophotometer (Eppendorf, Hamburg,
Germany). Real-time qRT-PCR was carried out with a
SYBR Green One-Step qRT-PCR kit (Invitrogen Inc.,
Carlsbad, CA, USA) according to the manufacturer's
instructions. The sequences of primers were shown in
Table 2. Internal calibration curves were generated by
the real time software. A melting curve analysis was car-
ried out between 60°C and 95°C with a plate read everyTable 2 Sequences of the primers for Real-time qRT-PCR
Gene Sequences (5’–3’) Product size (bp)
VEGF F: CCATGAACTTTCTGCTGTCTT 250
R: ATCGCATCAGGGGCACACAG
KSP F: CTGAACAGTGGGTATCTTCCTTA 480
R: GATGGCTCTTGACTTAGAGGTTC
Cyclin D1 F: GCCCGAGGAGCTGCTGCAAA 358
R: CCTGGCGCAGGCTTGACTCC
Bcl-2 F: CGGTGCCACCTGTGGTCCAC 174
R: TCCCCCAGTTCACCCCGTCC
Survivin F: GGACCGCCTAAGAGGGCGTGC 145
R: AATGTAGAGATGCGGTGGTCCTT
ANG2 F: TGGGATTTGGTAACCCTTCA 234
R: GTAAGCCTCATTCCCTTCCC
β-actin F : ACACTGTGCCCATCTAGGAGG 680
R: AGGGGCCGGACTCGTCATACT
F and R are Forward and Reverse, respectively.0.5°C after holding the temperature for 20 seconds. The
cycle number (Ct) at which the signals crossed a threshold
set within the logarithmic phase and the peaks of melting
curves were recorded. The relative quantitation of gene
expression in terms of fold change was calculated using
the 2-ΔΔCt method [35]. Relative expression levels of the
target genes in each treatment group were derived from
normalizing the Ct value of the target genes against that
of an endogenous reference (β-actin) and a calibrator
(control cells).
Western blot
After washing with cold PBS, the cells were lysed by a lysis
buffer containing 0.01M Tris, pH 7.5, 0.1M NaCl, 1%
Triton X-100, 0.5% sodium deoxycholate, and 0.1% so-
dium dodecyl sulfate (SDS), with added protease inhibi-
tors. Total proteins in cell lysates were separated by 10%
SDS-polyacrylamide gel electrophoresis (PAGE) and trans-
ferred to a polyvinylidene fluoride (PVDF) blotting
membrane (Sigma-Aldrich, St. Louis, MO, USA). The
membranes were blocked in blocking solution BSA
(Sigma-Aldrich, St. Louis, MO, USA) and incubated
with mouse anti-Eg5/KSP monoclonal antibody (1:200),
mouse anti-VEGF monoclonal antibody (1:200), mouse
anti-Cyclin D1 monoclonal antibody (1:500), mouse anti-
Bcl-2 monoclonal antibody (1:500), mouse anti-Survivin
monoclonal antibody (1:500), mouse anti-ANG2 mono-
clonal antibody (1:200) (All were bought from Abcam,
Cambridge, ENG, UK) for 1 hour at room temperature.
After washing, the membranes were incubated for 45
minutes with horseradish peroxidase (HRP)-linked goat
anti-mouse IgG (1:5000, Sigma-Aldrich, St. Louis, MO,
USA). The protein bands were visualized by enhanced
chemiluminescence (Sigma-Aldrich, St. Louis, MO,
USA). Mouse monoclonal Ab against β-actin (Abcam,
Cambridge, ENG, UK) was used as a housekeeping gene
control. Band intensities were semi-quantitatively analyzed
by Image J densitometer (NIH, Bethesda, MD, USA).
Enzyme linked immunosorbent assay (ELISA)
The amount of VEGF in cell supernatants was measured
by using human VEGF ELISA kit (Life Technologies,
Carlsbad, CA, USA) following the manual of the kit. The
human VEGF ELISA kit is a “sandwich” enzyme immuno-
assay employing monoclonal and polyclonal antibodies.
Quantitation can be determined by constructing an abso-
lute standard curve using known concentrations of human
VEGF proteins.
Cell proliferation assay
Cell proliferation was measured by WST-1 assay kit
(Roche, Basel, Switzerland). Briefly, siRNAs transfected
cells and control cells were seeded at a concentration
of 3 × 103 cells per well in 96-well plates (Corning Inc.,
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plied at 10 μl per well and incubated for 4 hours at 37°C,
5% CO2. The absorbance was measured with a microplate
ELISA reader (BioTek, Winooski, VT, USA) at 450 nm.
Clonogenic survival assay
Cells were seeded at a density of 500 cells per well in 6-
well plates (Corning Inc., NY, USA) contained complete
medium followed by treatment with siRNAs. The medium
was then replaced with fresh medium and incubated for an
additional 10 days. Clones were fixed with 4% paraformal-
dehyde for 30 minutes and stained with Crystal Violet
(Sigma-Aldrich, St. Louis, MO, USA) for about 15 minutes.
Stained clones that had more than 50 cells were counted at
low magnification.
Wound-healing assay
Cell migration was measured by wound-healing assay.
Hep3B cells were seeded and transfected with siRNAs as
described above in 24-well plates (Corning Inc., NY, USA)
at the density of 5 × 104 cells per well. After 48 hours,
wound was made through confluent monolayer cells with
a pipette tip. Wounded monolayers were then washed
with PBS, and incubated in DMEM-F12 without FBS.
Photographs of cells were taken at 0, 24, 48, and 72
hours to monitor cell movements.
Transwell invasion assay
Cell invasion was carried out by transwell assays. The
upper surface of the transwell filters (Corning Inc., NY,
USA) was coated with matrigel (BD Biosciences, Franklin
Lakes, NJ, USA). The siRNAs treated cells and control
cells (1 × 105 cells) were suspended in 200 μl serum-free
media, and then added to the chamber. The chamber
afterthat was placed in a 24-well plate containing complete
medium. After 48 hours of incubation at 37°C, the filters
were gently taken out and matrigel on the upper surface
of the filters was removed by cotton swabs. Cells on the
underside of transwell filters were fixed with 4% parafor-
maldehyde for 30 minutes, stained with Crystal Violet
(Sigma-Aldrich, St. Louis, MO, USA) for 10 minutes, and
then photographed. For quantitative assessment, the num-
ber of invading cells was counted from five randomly
selected visual fields per filter.
Apoptosis assay
Apoptosis was investigated by flow cytometry using annexin
V and propidium iodide (PI) (BD Biosciences, Franklin
Lakes, NJ, USA). Briefly, the cell concentration was firstly
adjusted to 1 × 106 cells/ml, and then 1 ml of the cell
suspension was taken and centrifuged at 500 × g for 10
minutes at 4°C. The pellet was rinsed twice with PBS
and then re-suspended in a proper volume of binding
buffer so that the cell concentration was 5 × 104 cells/ml.After addition of 10 μl Annexin V-FITC and 5 μl PI
followed by gentle mix, a 15 minute reaction was initiated
at room temperature in darkness. After that, 300 μl bind-
ing buffer was added and flow cytometry (FACSCalibur)
using CellQuest Pro software (BD Biosciences, Franklin
Lakes, NJ, USA) was performed to detect cell apoptosis
rate (%).
Tube formation assay
The ability of endothelial cells to sprout new blood vessels
stimulated by pro-angiogenic factors released from Hep3B
cells was examined in HUVECs angiogenesis in vitro model.
Briefly, 6 × 104 HUVECs were collected, resuspended in a
conditioned medium, which was the supernatant of siRNAs
treated Hep3B cells, seeded in 24-well plates coated with
100 μl Matrigel (BD Biosciences, Franklin Lakes, NJ, USA),
and cultured at 37°C, 5% CO2. After incubation for 24
hours, numbers of branching points were counted.
Statistical analysis
Each experiment was performed in triplicate for all data
(n = 3). Data was expressed as mean ± standard error of
the mean. Statistical comparisons were performed using
the Student’s t –test and ANOVA. p -values < 0.05 were
considered to be statistically significant.
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